» Articles » PMID: 36235145

Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Oct 14
PMID 36235145
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the leading causes of morbidity and mortality around the globe and is likely to become the major cause of global death in the coming years. As per World Health Organization (WHO) report, every year there are over 10 and 9 million new cases and deaths from this disease. Chemotherapy, radiotherapy, and surgery are the three basic approaches to treating cancer. These approaches are aiming at eradicating all cancer cells with minimum off-target effects on other cell types. Most drugs have serious adverse effects due to the lack of target selectivity. On the other hand, resistance to already available drugs has emerged as a major obstacle in cancer chemotherapy, allowing cancer to proliferate irrespective of the chemotherapeutic agent. Consequently, it leads to multidrug resistance (MDR), a growing concern in the scientific community. To overcome this problem, in recent years, nanotechnology-based drug therapies have been explored and have shown great promise in overcoming resistance, with most nano-based drugs being explored at the clinical level. Through this review, we try to explain various mechanisms involved in multidrug resistance in cancer and the role nanotechnology has played in overcoming or reversing this resistance.

Citing Articles

A protracted war against cancer drug resistance.

Tian Y, Wang X, Wu C, Qiao J, Jin H, Li H Cancer Cell Int. 2024; 24(1):326.

PMID: 39342202 PMC: 11439304. DOI: 10.1186/s12935-024-03510-2.


Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin.

Plonka-Czerw J, Zyrek L, Latocha M Molecules. 2024; 29(15).

PMID: 39124936 PMC: 11313889. DOI: 10.3390/molecules29153531.


The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer.

Wilczak M, Surman M, PRZYBYlO M Curr Pharm Des. 2024; 30(35):2765-2784.

PMID: 39113303 DOI: 10.2174/0113816128326325240723051625.


Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells.

Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal S Cancers (Basel). 2024; 16(13).

PMID: 39001539 PMC: 11240358. DOI: 10.3390/cancers16132478.


Nanotechnology as a Promising Method in the Treatment of Skin Cancer.

Adamus-Grabicka A, Hikisz P, Sikora J Int J Mol Sci. 2024; 25(4).

PMID: 38396841 PMC: 10889690. DOI: 10.3390/ijms25042165.


References
1.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

2.
Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

3.
Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J, Maloisel F . Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997; 337(4):223-9. DOI: 10.1056/NEJM199707243370402. View

4.
Yang B, Hao A, Chen L . Mirror siRNAs loading for dual delivery of doxorubicin and autophagy regulation siRNA for multidrug reversing chemotherapy. Biomed Pharmacother. 2020; 130:110490. DOI: 10.1016/j.biopha.2020.110490. View

5.
Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View